Eikon Therapeutics reported updated clinical data for its TLR7/8 agonist EIK1001. In NSCLC patients, the combination with pembrolizumab and chemotherapy demonstrated a durable effect with an encouraging safety profile, a key differentiator from previous therapies. The company also noted their ongoing Phase 2/3 trial.